CN1669559A - Medicine for treating rhinitis - Google Patents
Medicine for treating rhinitis Download PDFInfo
- Publication number
- CN1669559A CN1669559A CN 200410026526 CN200410026526A CN1669559A CN 1669559 A CN1669559 A CN 1669559A CN 200410026526 CN200410026526 CN 200410026526 CN 200410026526 A CN200410026526 A CN 200410026526A CN 1669559 A CN1669559 A CN 1669559A
- Authority
- CN
- China
- Prior art keywords
- medicine
- rhinitis
- weight
- treatment
- sodium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Disclosed is a medicine for treating rhinitis which comprises, 1-10 wt% of sodium hydrogen carbonate, 1-10 wt% sodium chloride. The medicament can keep the nasal cavity in a weak base environment with relative stability, so as to prevent the injury by acidic environment to cilium movement in the nose
Description
Technical field
The present invention relates to a kind of medicine, particularly a kind of medicine that is used for the treatment of the preceding rhinitis of drying property.
Background technology
This difficult disease of rhinitis sickness rate in people's life increases day by day, traditional view thinks that rhinitis is infectivity or anaphylactic disease, stress the research of anaphylactogen and inflammation treatment, but ignored especially rhinitis before one of inducement----drying property of chronic rhinitis of coryza.
Rhinitis is a kind of chronic disease before the drying property, directly be created in the dried mucositis at membranous mucocutaneous edge, but other parts of intranasal side is normal.Patient reflects that the intranasal sensation is dry, itch, form crust, epistaxis and form ulcer.Attend by the formation of pseudomembrane or crust in the time of epistaxis, nasal mucosa presents little yellow or brown; And ulcer finally causes the barrier film perforation, produces tangible respiratory disorder.If but the drug main of existing treatment rhinitis is at infectivity or allergic rhinitis, not the medicine that rhinitis before the drying property is had a good therapeutic effect.
Summary of the invention
The objective of the invention is to overcome the above-mentioned deficiency of prior art, and propose that a kind of therapeutic effect is good, the medicine that is used for the treatment of rhinitis before the drying property of stable curative effect and few side effects.
Purpose of the present invention can reach by taking following technical measures:
A kind of medicine that is used for the treatment of rhinitis, described medicine contain the sodium bicarbonate of 1-10% (weight) and the sodium chloride of 1-10% (weight).
Compared with prior art, medicine of the present invention remains under the metastable weakly alkaline environment nasal cavity, avoids the infringement of sour environment to the intranasal cilia activity; Medicine can promote forming naturally of secretions, does not absorb the moisture of nasal cavity, makes nasal cavity keep moistening, suppresses the endocrine evaporation of nasal cavity again simultaneously, has no side effect, and for rhinitis before the drying property curative effect and effect stability is preferably arranged.
The specific embodiment
A kind of medicine that is used for the treatment of rhinitis, described medicine contain the sodium bicarbonate of 1-10% (weight) and the sodium chloride of 1-10% (weight).Sodium bicarbonate is regulated the inside and outside various electrolyte balances of cell of the buffer system of health, and the mixing ratio of sodium chloride salt and sodium bicarbonate salt uses salt to produce lower permeability separately, promotes the endocrine formation naturally of nasal cavity by osmosis; And the sodium bicarbonate of 1-10% and the sodium chloride of 1-10% make nasal cavity remain under a metastable alkalescence (PH is in the 7.1-8.9 scope) environment, avoid the infringement of sour environment to the intranasal cilia activity, and weakly alkaline environment can strengthen the movable function of epithelium cilium, be beneficial to ciliary movement for mucus and the cleaning of himself, better tolerance, side effect is little.
The described medicine that is used for the treatment of rhinitis also comprises auxiliary components, and its auxiliary components comprises one of a mao fat ethanol, Fructus Citri Limoniae oil, paraffinum molle alba, medium chain triglyceride, liquid paraffin and whale stearic acid ethanol at least.Auxiliary components is made ointment or gel as the carrier of sodium bicarbonate and sodium chloride with medicine.Described auxiliary components suppresses the endocrine evaporation rate of nasal cavity and keeps liquid state, makes the nasal cavity environment keep moistening, and cilium can not stick together, and for rhinitis before the drying property curative effect and effect stability is preferably arranged;
Get oil-phase component Fructus Citri Limoniae oil 0.1g, paraffinum molle alba 60.84g, medium chain triglyceride 27.8g, liquid paraffin 0.4g in water-bath (75-80 ℃) heating and melting;
Water intaking phase constituent hair fat ethanol 0.8g, whale stearic acid ethanol 0.06g, sodium chloride 2.8g, the 7.2g sodium bicarbonate is regulated the water-phase component pH value to 8.2-8.3, water-bath (75-80 ℃) heating;
When oil phase is identical with the water temperature, oil phase is added aqueous phase, constantly slowly be stirred to condensation along same direction, promptly get described medicine.Can further carry out assay, centrifugal test and percutaneous permeability test, afterwards with the drugs packaging embedding to described medicine.Described property of drug denseness is moderate, and good stability is heat-resisting, low temperature resistant, and 3750 rev/mins of centrifugal test profits are not stratified, and Transdermal absorption is good.
The pharmaceutical applications that will have above-mentioned weight proportion is in clinical, and details are as follows for relevant clinical therapeutic efficacy.
Table 1: the curative effect assessment behind the use medicine
| The curative effect assessment | Patient's percentage ratio (%) | ||||
| Symptom is eliminated | Symptom is significantly improved | Doing well,improving | The statistics total effective rate | Do not have and improve | |
| The normality of secretions | ????18.8 | ????39.3 | ????32.2 | ????90.3 | ????9.7 |
| Disappearing of crust | ????25.1 | ????48.4 | ????23.5 | ????96.9 | ????3.1 |
| The regeneration of nasal mucosa injury | ????20.4 | ????34.1 | ????33.2 | ????87.8 | ????12.2 |
| The obstruction of nasal respiration | ????22.8 | ????31.7 | ????31.8 | ????86.3 | ????13.7 |
| The biorgan functional rehabilitation | ????19.5 | ????31.5 | ????38.1 | ????89.2 | ????10.8 |
| Epistaxis | ????61.8 | ????16.2 | ????15.5 | ????93.4 | ????6.6 |
The patient is carried out the result of subjective survey: 95.4% patient evaluation is that doing well,improving arrives the symptom elimination; There is not arbitrary case serious adverse to occur being regarded as; 97.4% patient evaluation medicine toleration is very good or good; 91.1% patient is evaluated as very good to therapeutic outcome or is good; To the observation of peculiar situation, report has the people that remarkable minimizing is arranged aspect snoring.
With reference to table 1, medicine is to the effect aspect of rhinitis, has 90% case doing well,improving to eliminate up to symptom.This therapeutic outcome can be regarded as great clinical meaning, this also with the subjective survey outcome evaluation have patient's doing well,improving of 95.4% to symptom eliminate, 97.4% patient tolerability is that patient evaluation therapeutic outcome very good or good, 91.1% is very good or is consistent well;
Aspect crust disappeared, clinical effectiveness was the most obvious, had patient's symptom of 73.5% to eliminate or obviously improve, and had only 3.1% patient not improve.
Claims (3)
1. medicine that is used for the treatment of rhinitis is characterized in that:
Described medicine contains the sodium bicarbonate of 1-10% (weight) and the sodium chloride of 1-10% (weight).
2. the medicine that is used for the treatment of rhinitis according to claim 1 is characterized in that: the content of described sodium bicarbonate and sodium chloride is respectively 7.2% (weight) and 2.8% (weight).
3. the medicine that is used for the treatment of rhinitis according to claim 1 and 2 is characterized in that:
Described medicine also comprises auxiliary components, and its auxiliary components comprises one of a mao fat ethanol, Fructus Citri Limoniae oil, paraffinum molle alba, medium chain triglyceride, liquid paraffin and whale stearic acid ethanol at least.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410026526 CN1669559A (en) | 2004-03-15 | 2004-03-15 | Medicine for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410026526 CN1669559A (en) | 2004-03-15 | 2004-03-15 | Medicine for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1669559A true CN1669559A (en) | 2005-09-21 |
Family
ID=35041136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410026526 Pending CN1669559A (en) | 2004-03-15 | 2004-03-15 | Medicine for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1669559A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547044A (en) * | 2014-12-22 | 2015-04-29 | 章迅 | Medicinal composition for preventing and treating upper respiratory inflammation and preparation and application thereof |
| EP3043650A4 (en) * | 2013-09-10 | 2017-11-08 | Kenneth P. Glynn | Carbon dioxide and saline nasal delivery methods and delivery devices |
| CN110179843A (en) * | 2019-04-23 | 2019-08-30 | 昆明医科大学 | External-use pharmaceutical composition for treating non-allergic rhinitis |
| WO2022110619A1 (en) * | 2020-11-26 | 2022-06-02 | 江苏泰德医药有限公司 | Product and preparation method for prevention and treatment of novel coronavirus |
-
2004
- 2004-03-15 CN CN 200410026526 patent/CN1669559A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3043650A4 (en) * | 2013-09-10 | 2017-11-08 | Kenneth P. Glynn | Carbon dioxide and saline nasal delivery methods and delivery devices |
| CN104547044A (en) * | 2014-12-22 | 2015-04-29 | 章迅 | Medicinal composition for preventing and treating upper respiratory inflammation and preparation and application thereof |
| CN110179843A (en) * | 2019-04-23 | 2019-08-30 | 昆明医科大学 | External-use pharmaceutical composition for treating non-allergic rhinitis |
| WO2022110619A1 (en) * | 2020-11-26 | 2022-06-02 | 江苏泰德医药有限公司 | Product and preparation method for prevention and treatment of novel coronavirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2368974T3 (en) | PREPARATION CONTAINING OSMOLITES FOR USE IN CASE OF DRY MUCOUS MEMBRANES. | |
| Thornhill et al. | Natural treatment of perennial allergic rhinitis | |
| Hulisz | Efficacy of zinc against common cold viruses: an overview | |
| ES2244831T3 (en) | PHARMACEUTICAL COMPOSITION FOR OPHTHALMOLOGICAL AND RHINOLOGICAL APPLICATION. | |
| CN105792828A (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| US10350233B2 (en) | Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions | |
| CN105168119A (en) | Compound nasal inhalation gel preparation for treating rhinitis | |
| BR0117197A (en) | Drug formulation containing cyclosporine application of same | |
| CN1669559A (en) | Medicine for treating rhinitis | |
| CN108366991B (en) | Synergistic compound of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof for the treatment and/or prevention of dryness and irritation of mucous membranes, and related pharmaceutical formulations | |
| CN1302813C (en) | Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method | |
| CN105056290B (en) | A kind of medical bio hydrogel functional dressings and preparation method thereof | |
| WO1994005272A1 (en) | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide | |
| CN101601768B (en) | Chinese medicinal composition for treating tinea pedis and scabies and preparation method thereof | |
| KR101988283B1 (en) | Gel composition for pain relief comprising kidney stone powder | |
| US10959964B2 (en) | Use of a sprayable composition comprising ambroxol | |
| CN108261523A (en) | A kind of Chinese medicine composition and method for treating allergic rhinitis | |
| US12016941B2 (en) | Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms | |
| CN112156134B (en) | Use of Piper laetispicum extract for preparing hyaluronidase inhibitor | |
| CN1277551C (en) | Mint oil preparation for treating obstructive sleep apnea and low ventilation syndrome | |
| CN105998150A (en) | Neurodermatitis treating medicine | |
| WO2024146967A1 (en) | Ternary inclusion complex comprising rutin, arginine and zinc gluconate, production method and use | |
| KR20230167255A (en) | Functional food composition for improving and preventing bronchial inflammation containing Nigella sativa seed oil and omega 3 oil. | |
| US20220143072A1 (en) | Chitosan nitrate for use as a nitric oxide donor (NO donor) | |
| TW201249427A (en) | Use of sprayable composition containing ambroxol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |